Please assess the completion status of the following clinical trial:

Trial Title: Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female 18 to 80 years of age;~* Previously met the preliminary criteria of American Rheumatism Associatio (ARA) for the classification of acute gout arthritis of primary gout;~* Subjects with history of gout, initiating or currently on urate lowering; therapy who are at risk of gout flare.~Exclusion Criteria:~* Acute gout flare within 2 weeks prior to the screening visit and during the screening visit;~* Persistent chronic or active infections;~* History of an allergic reaction to allopurinol;~* History or presence of cancer within 5 years of the Screening Visit;;;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 15.
- Rilonacept 160 mg (Type: EXPERIMENTAL): Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 15.

Based on this trial design, predict the completion outcome and termination type (if applicable).